Moreover, inhibitors of DHODH, including leflunomide, are also considered to combat RNA virus infections (Deans et al., 2016; Xiong et al., 2020) and have now entered clinical trials for coronavirus disease 2019 (COVID-19) (clinicaltrials.gov). Here, DHODH is linked to COVID-19.